A citation-based method for searching scientific literature

Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi, Gene Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel Lopez-Chavez, Alan Sandler, Martin Reck. N Engl J Med 2018
Times Cited: 1394



Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer. N Engl J Med 2016
Times Cited: 4612




List of shared articles



Times cited

Advances in Small-Cell Lung Cancer (SCLC) Translational Research.
Benjamin J Drapkin, Charles M Rudin. Cold Spring Harb Perspect Med 2021
3

Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
Akihiro Tamiya, Shun-Ichi Isa, Yoshihiko Taniguchi, Hideyuki Nakagawa, Shinji Atagi, Masahiko Ando, Yasuhiro Koh. Clin Lung Cancer 2021
0

Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Tomoaki Muramatsu, Takuro Noguchi, Daisuke Sugiyama, Yoshie Kanada, Kaori Fujimaki, Sachiko Ito, Momokazu Gotoh, Hiroyoshi Nishikawa. Int Immunol 2021
0

Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors.
Yuan Wei, Xiao Xiao, Xiang-Ming Lao, Limin Zheng, Dong-Ming Kuang. Cell Mol Life Sci 2021
1

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms.
Mu-Yang Huang, Xiao-Ming Jiang, Bing-Lin Wang, Yang Sun, Jin-Jian Lu. Pharmacol Ther 2021
5

Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Ranjan Pathak, Gilberto De Lima Lopes, Han Yu, Madan Raj Aryal, Wenyan Ji, Katherine Stemmer Frumento, Christopher J D Wallis, Zachary Klaassen, Henry S Park, Sarah B Goldberg. Cancer 2021
2

Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer.
Yuri Ogura, Nobutaka Kataoka, Yusuke Kunimatsu, Yusuke Tachibana, Takumi Sugimoto, Nozomi Tani, Izumi Sato, Kazuki Hirose, Daishiro Kato, Takayuki Takeda. Thorac Cancer 2021
0


The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou. Cell Mol Immunol 2021
5

Brain metastases in metastatic cancer: a review of recent advances in systemic therapies.
Ariane Steindl, Anna S Berghoff. Expert Rev Anticancer Ther 2021
3

Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Taisuke Isono, Naho Kagiyama, Kenji Takano, Chiaki Hosoda, Takashi Nishida, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Youtaro Takaku, Kazuyoshi Kurashima,[...]. Thorac Cancer 2021
4


Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Tom L Enright, Jacob S Witt, Adam R Burr, Poonam Yadav, Ticiana Leal, Andrew M Baschnagel. Clin Lung Cancer 2021
1

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
Caicun Zhou, Yina Wang, Jun Zhao, Gongyan Chen, Zhihua Liu, Kangsheng Gu, Meijuan Huang, Jianxing He, Jianhua Chen, Zhiyong Ma,[...]. Clin Cancer Res 2021
11

Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients.
Kyung-In Joung, Jong Hwa Song, Kangho Suh, Seung-Mi Lee, Ji Hyun Jun, Taehwan Park, Dong Churl Suh. BioDrugs 2021
0

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, Bruno Daniele, Michael Dougan, Leisha A Emens, Silvia Formenti, Filip Janku, Samir N Khleif, Tomas Kirchhoff,[...]. J Transl Med 2021
0

Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
Han Li, Jinsheng Xu, Yaling Bai, Shenglei Zhang, Meijuan Cheng, Jingjing Jin. Invest New Drugs 2021
2

Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Riccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, Giacomo Massa, Maria Lucia Iacovino, Francesca Sparano, Carminia Maria Della Corte, Roberto Ferrara, Diego Signorelli, Claudia Proto,[...]. Lung Cancer 2021
3

Antitumour immunity regulated by aberrant ERBB family signalling.
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa. Nat Rev Cancer 2021
11


Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer.
Masafumi Yamaguchi, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Satoshi Shiono, Hiroshige Yoshioka, Tadashi Aoki,[...]. Jpn J Clin Oncol 2021
1

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem,[...]. Oncoimmunology 2021
2

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
Meng Qiao, Fei Zhou, Likun Hou, Xuefei Li, Chao Zhao, Tao Jiang, Guanghui Gao, Chunxia Su, Chunyan Wu, Shengxiang Ren,[...]. Ann Transl Med 2021
3

Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Angelo Borsarelli Carvalho Brito, Marcos Pedro Guedes Camandaroba, Vladmir Cláudio Cordeiro de Lima. Thorac Cancer 2021
1

Immunotherapy in lung cancer.
Gabriela Bravo Montenegro, Saira Farid, Stephen V Liu. J Surg Oncol 2021
2

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen V Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem,[...]. J Immunother Cancer 2021
4

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
36

A Method for the Establishment of Human Lung Adenocarcinoma Patient-Derived Xenografts in Mice.
Joanne Lundy, Brendan J Jenkins, Mohamed I Saad. Methods Mol Biol 2021
0

KRAS G12C inhibition and innate immune targeting.
Tetsuo Tani, Shunsuke Kitajima, Ella B Conway, Erik H Knelson, David A Barbie. Expert Opin Ther Targets 2021
0

Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting.
Manglio Miguel Rizzo, María Virginia Bluthgen, Gonzalo Recondo, Martin Naveira, Aldo Perfetti, Florencia Rizzi, Alejandro Kuzminin, Victoria Faura, Matías Cerini, Alejandro Videla,[...]. Int J Clin Oncol 2021
1

Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.
Fausto Petrelli, Roberto Ferrara, Diego Signorelli, Antonio Ghidini, Claudia Proto, Raheleh Roudi, Mehrdad N Sabet, Sara Facelli, Marina C Garassino, Andrea Luciani,[...]. Immunotherapy 2021
5

Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Naofumi Hara, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Shinobu Hosokawa, Daizo Kishino, Kawai Haruyuki, Nobuaki Ochi, Naohiro Oda,[...]. J Cancer Res Clin Oncol 2021
0

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Margarita Majem, Manuel Cobo, Dolores Isla, Diego Marquez-Medina, Delvys Rodriguez-Abreu, Joaquín Casal-Rubio, Teresa Moran Bueno, Reyes Bernabé-Caro, Diego Pérez Parente, Pedro Ruiz-Gracia,[...]. J Clin Med 2021
1


Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. J Clin Oncol 2021
15

Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
David Waterhouse, Jenny Lam, Keith A Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon Lubinga, David Stenehjem. Lung Cancer 2021
1

Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.
Yasuto Yoneshima, Satoshi Morita, Masahiko Ando, Atsushi Nakamura, Shunichiro Iwasawa, Hiroshige Yoshioka, Yasuhiro Goto, Masafumi Takeshita, Toshiyuki Harada, Katsuya Hirano,[...]. J Thorac Oncol 2021
2

Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations.
Motohiro Izumi, Kenji Sawa, Jun Oyanagi, Ikue Noura, Mitsuru Fukui, Koichi Ogawa, Yoshiya Matsumoto, Yoko Tani, Tomohiro Suzumura, Tetsuya Watanabe,[...]. Transl Oncol 2021
0

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.
Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui,[...]. Front Oncol 2021
2

Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment.
Jingtao Tong, Yifei Mao, Ziru Yang, Quan Xu, Zhen Zheng, Hui Zhang, Jingjing Wang, Sandian Zhang, Weibo Rong, Lu Zheng. Cancer Manag Res 2021
0